Lorenzo Barberis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lorenzo Barberis has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Abatini
Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
2 shared publications - Fabio Pacelli
General Surgery Department, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
2 shared publications - Francesco Santullo
Surgical Unit of Peritoneum and Retroperitoneum Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
2 shared publications - Giorgio D’Annibale
Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
2 shared publications - Alexia Spring
Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
1 shared publication - Antonia Strippoli
Medical Oncology, Comprehensive Cancer Centre, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
1 shared publication
Latest Publications
- Open Access
Minimally Invasive Versus Open CRS/HIPEC for Peritoneal Surface Malignancies: Postoperative Recovery and Long-Term Outcomes—A Systematic Review and Meta-Analysis
Background: Minimally invasive surgery (MIS) is increasingly implemented for cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies (PSM). This systematic review and meta-analysis compared minimally invasive CRS/HIPEC (M-CRS/HIPEC) and open CRS/HIPEC (O-CRS/HIPEC) in terms of perioperative, postoperative, and long-term oncological outcomes. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and the Cochrane Library were searched for comparative studies of M-CRS/HIPEC versus O-CRS/HIPEC in adult patients. Risk of bias was assessed using the Newcastle–Ottawa Scale and RoB 2.0. Pooled relative risks (RR) for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes were calculated with 95% confidence intervals (CI). Sensitivity analyses were performed to assess the potential influence of disease burden and primary tumor heterogeneity. Results: Twenty-one studies (1 randomized controlled trial and 20 retrospective cohorts) including 1184 patients (452 M-CRS/HIPEC and 732 O-CRS/HIPEC) were analyzed. Operative time did not differ between groups (SMD = 0.195; p = 0.667). Most cytoreductive procedures were comparable, although small bowel resections were less frequent with M-CRS/HIPEC (RR = 0.537; p = 0.018). The minimally invasive approach achieved higher CC0 rates (RR = 1.053; p = 0.045), with lower blood loss (SMD = −1.838; p < 0.001) and fewer transfusions (RR = 0.588; p = 0.002). Postoperative recovery favored M-CRS/HIPEC, with earlier return of bowel function and resumption of oral intake, shorter hospital stay, fewer readmissions, and earlier chemotherapy resumption (all p < 0.05). Overall and major morbidity were reduced, while postoperative mortality and 1-, 3-, and 5-year disease-free and overall survival did not differ significantly between groups. In the disease burden-restricted sensitivity analysis, differences in small bowel resection, CC0 rate, and 90-day readmission were no longer statistically significant, whereas the main perioperative and recovery benefits persisted. No significant differences in DFS or OS were identified in the additional sensitivity analyses at the evaluable time points. Conclusions: This meta-analysis supports a selective, expertise-driven use of M-CRS/HIPEC, offering perioperative and recovery advantages without significant differences in cytoreductive adequacy or long-term outcomes in appropriately selected patients.
Open AccessMinimally Invasive Versus Open CRS/HIPEC for Peritoneal Surface Malignancies: Postoperative Recovery and Long-Term Outcomes—A Systematic Review and Meta-Analysis
Background: Minimally invasive surgery (MIS) is increasingly implemented for cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies (PSM). This systematic review and meta-analysis compared minimally invasive CRS/HIPEC (M-CRS/HIPEC) and open CRS/HIPEC (O-CRS/HIPEC) in terms of perioperative, postoperative, and long-term oncological outcomes. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and the Cochrane Library were searched for comparative studies of M-CRS/HIPEC versus O-CRS/HIPEC in adult patients. Risk of bias was assessed using the Newcastle–Ottawa Scale and RoB 2.0. Pooled relative risks (RR) for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes were calculated with 95% confidence intervals (CI). Sensitivity analyses were performed to assess the potential influence of disease burden and primary tumor heterogeneity. Results: Twenty-one studies (1 randomized controlled trial and 20 retrospective cohorts) including 1184 patients (452 M-CRS/HIPEC and 732 O-CRS/HIPEC) were analyzed. Operative time did not differ between groups (SMD = 0.195; p = 0.667). Most cytoreductive procedures were comparable, although small bowel resections were less frequent with M-CRS/HIPEC (RR = 0.537; p = 0.018). The minimally invasive approach achieved higher CC0 rates (RR = 1.053; p = 0.045), with lower blood loss (SMD = −1.838; p < 0.001) and fewer transfusions (RR = 0.588; p = 0.002). Postoperative recovery favored M-CRS/HIPEC, with earlier return of bowel function and resumption of oral intake, shorter hospital stay, fewer readmissions, and earlier chemotherapy resumption (all p < 0.05). Overall and major morbidity were reduced, while postoperative mortality and 1-, 3-, and 5-year disease-free and overall survival did not differ significantly between groups. In the disease burden-restricted sensitivity analysis, differences in small bowel resection, CC0 rate, and 90-day readmission were no longer statistically significant, whereas the main perioperative and recovery benefits persisted. No significant differences in DFS or OS were identified in the additional sensitivity analyses at the evaluable time points. Conclusions: This meta-analysis supports a selective, expertise-driven use of M-CRS/HIPEC, offering perioperative and recovery advantages without significant differences in cytoreductive adequacy or long-term outcomes in appropriately selected patients.
- Open Access
Navigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing on a standardized treatment algorithm and on pre-operative cisplatin–pemetrexed as a bridge to cytoreductive surgery and HIPEC. Methods: Consecutive patients treated between 2016 and 2024 were retrospectively reviewed. Treatment allocation was based on diagnostic laparoscopy, PCI assessment, and multidisciplinary evaluation. Patients with technically resectable disease underwent upfront CRS–HIPEC, whereas borderline or unresectable patients received cisplatin–pemetrexed followed by systematic reassessment. Results: Forty-three patients were included; 19 underwent CRS–HIPEC, including 8 after pre-operative chemotherapy, and 24 received medical management alone. Curative-intent cytoreduction (CC-0/1) was achieved in all operated patients, with no 30-day mortality. No statistically significant difference in overall survival was detected between upfront and conversion surgery patients in this small cohort. Higher PCI and Ki-67 were independently associated with worse overall survival. Conclusions: A structured multidisciplinary pathway may support tailored treatment selection in epithelioid diffuse malignant peritoneal mesothelioma. In selected responders, cisplatin–pemetrexed may act as a bridge to surgery, although larger studies are required to validate this strategy.
Open AccessNavigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing on a standardized treatment algorithm and on pre-operative cisplatin–pemetrexed as a bridge to cytoreductive surgery and HIPEC. Methods: Consecutive patients treated between 2016 and 2024 were retrospectively reviewed. Treatment allocation was based on diagnostic laparoscopy, PCI assessment, and multidisciplinary evaluation. Patients with technically resectable disease underwent upfront CRS–HIPEC, whereas borderline or unresectable patients received cisplatin–pemetrexed followed by systematic reassessment. Results: Forty-three patients were included; 19 underwent CRS–HIPEC, including 8 after pre-operative chemotherapy, and 24 received medical management alone. Curative-intent cytoreduction (CC-0/1) was achieved in all operated patients, with no 30-day mortality. No statistically significant difference in overall survival was detected between upfront and conversion surgery patients in this small cohort. Higher PCI and Ki-67 were independently associated with worse overall survival. Conclusions: A structured multidisciplinary pathway may support tailored treatment selection in epithelioid diffuse malignant peritoneal mesothelioma. In selected responders, cisplatin–pemetrexed may act as a bridge to surgery, although larger studies are required to validate this strategy.